The 6-(4-Aminophenyl)-4,5-dihydro-3(2H)-pyridazinone moiety is a crucial structural component for the development of various cardioactive agents, including levosimendan and pimobendan.
Answers are grounded in this paper and cite their sources.
May inform pyridazinone scaffold design for cardioactive agents; leaves open prospective validation of novel derivatives.
6-(4-Aminophenyl)-4,5-dihydro-3(2H)-pyridazinone moiety is a vital structural part of many cardio-active pyridazinone derivatives which are either in clinical use or have been tested in clinical trials. These include imazodan, CI-930, pimobendan, indolidan, levosimendan, SK&F-93741, Y-590, meribendan, NSP-804, NSP-805, bemoradan, senazodan, amipizone, prinoxodan, SKF 95654, siguazodan and KF 15232. This article briefly reviews relevant literature on various reports on the synthesis and use of thismoiety for development of cardio-active agents.
No takes yet. Share an insight, caveat, or question.
Mohd Imran (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: